Doximity, Inc. (DOCS): what the price assumes

In the published model solve dated 2026-Q2, anchored at $26.73, Doximity, Inc. (DOCS) is priced for today's economics sustained for ~8.4 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-08-07.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/DOCS

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 6: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 11.7% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: n/a

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=15)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• More than 85% of U.S. physicians are verified members of a network that sells access to them, and about 95% of revenue in the nine months to December 2025 came from subscription customers rather than one-off placements.
• Profitability is going the wrong way while revenue grows: operating income fell to 214.9 million dollars in the fiscal year ended March 31, 2026 from 227.8 million the year before, even as revenue rose to 644.9 million from 570.4 million.
• The June 2026 quarter is where that shows most sharply, with income from operations of 33.6 million dollars against 54.5 million a year earlier, and management guiding the September quarter to revenue of 170 to 171 million dollars.

Bull Case

Start with what management does with the money, because it is unusually revealing here. Doximity carries no funded borrowings at all. It holds 748.6 million dollars in cash and marketable securities. And in the June 2026 quarter alone it spent 91.6 million dollars buying back its own shares, after 122.4 million in the same quarter a year earlier. The diluted share count fell from 201.2 million to 191.2 million over that year. A company with no debt to repay, no dividend to defend and no acquisitions to fund is telling you where it thinks the best available asset is.

It can do that because the business consumes almost nothing. Revenue of 644.9 million dollars in the fiscal year ended March 31, 2026 required no factories, no inventory and no field force of consequence. The entire balance sheet totals 1,083.8 million dollars, of which the largest single item is the investment portfolio. Property and equipment is 19.2 million. Cash conversion follows from that shape rather than from any accounting choice.

The asset itself is a membership roster that would be close to impossible to rebuild. The company states that its "network members include more than 85% of U.S. physicians across all specialties and practice areas", each one identity-verified. Pharmaceutical manufacturers and health systems do not buy advertising space here; they buy reach into a professional audience that no general platform can authenticate. The 10-K describes customers who "initially run marketing programs for a certain number of brands, but have a track record of increasing their" commitment over time, which is the land-and-expand pattern in its most literal form. Revenue per existing marketing customer rose roughly 13% in the nine months to December 2025.

That revenue is also structurally sticky. Approximately 95% of revenue in that period came from subscription customers, billed in advance and recognized ratably. Deferred revenue of 109.1 million dollars sits on the balance sheet as work already paid for. Compare the profitability this produces with the cohort: VEEV, the largest comparable healthcare software business, runs a 28.8% operating margin on 3.32 billion dollars of revenue; WAY runs 22.9% on 1.21 billion; HNGE, growing fastest of the three, runs deeply negative margins on 476 million. Doximity earned 33.3% in the fiscal year ended March 31, 2026, the best of the group on a fraction of the revenue.

The bear will point to the June quarter, where operating income fell by more than a third. The composition of that decline matters. Stock compensation in the quarter rose to 36.8 million dollars from 21.9 million, and research and development spending rose 43.6% to 38.5 million, most of it directed at the clinical AI products the company has begun putting numbers against: workflow active prescriber growth above 30% year over year and AI search query growth above 25% quarter over quarter. Spending that lands in the income statement immediately and pays back over years always looks like margin failure in the quarter it happens.

Which brings the argument to the price. Adjusting for the investment portfolio, the market values the operating business at roughly 17 times the operating income of the fiscal year just ended. The methods that credit peer multiples and forward growth both reach that price comfortably. For a debt-free business with a third of revenue falling to operating profit and a customer base that cannot be replicated, that is not an obviously heroic ask.

Bear Case

The margin the market is looking at may be the best one this business will show for a while. In the fiscal year ended March 31, 2025 Doximity earned 227.8 million dollars of operating income on 570.4 million of revenue. In the year ended March 31, 2026 revenue rose to 644.9 million while operating income fell to 214.9 million, a margin of 33.3%. In the June 2026 quarter, operating income was 33.6 million on revenue of 156.6 million, or about 21%. Revenue up, profit down, three periods running. Software businesses are supposed to work the other way.

The customer base is where the fragility sits. The 10-K is direct that "our revenue is relatively concentrated within a small number of key customers", and adds that some of those customers buy indirectly through marketing agencies representing several others, which compounds rather than diversifies the exposure. Pharmaceutical marketing budgets are set annually by a small number of large manufacturers, and those budgets move with drug launch cycles, patent expiries and pricing policy. A platform that reaches nearly every physician in the country still depends on a small number of organizations willing to pay for that reach.

Set that against what the price asks. The market is paying roughly 17 times the operating income of the fiscal year ended March 31, 2026, which at an 11.6% cost of capital works out to operating growth held at its self-funding ceiling for about six years. The company's own record says the near-term pace is achievable; the stretch is duration rather than rate. But of comparable fast growers, only around 30% sustained that pace even that long, and the assessment behind that reads on three of four available comparisons, resting mainly on the company's own history and the survival rate of fast growers. A thinner check makes the claim weaker, not milder. Six years of uninterrupted compounding is a long time for a business whose revenue growth just printed 7%.

The cost line has changed shape, and not temporarily. Cost of revenue rose 50% in the June quarter while revenue rose 7%. Research and development rose 43.6%. Stock compensation of 36.8 million dollars in a single quarter is running at nearly a quarter of revenue, which means reported operating profit and the cash the owners actually keep are drifting apart. The buyback partially masks that: repurchases of 91.6 million dollars in the quarter cut the share count, but a meaningful share of the spending is simply absorbing the stock being issued to employees rather than concentrating ownership.

There is a competitive dimension the filings acknowledge without quantifying. Doximity is now selling AI-powered clinical search and reference tools into a market where the largest technology companies give comparable capability away, and where the underlying medical literature is not proprietary to anyone. The company's advantage is the verified physician network, not the model. If the products that drove the June quarter's spending increase turn out to be table stakes rather than a new revenue line, the margin compression stays and the growth does not arrive.

What does bound the downside is the balance sheet. There is no funded debt, and cash and marketable securities of 748.6 million dollars covered every liability on the books several times over at the March 2026 year end. This is not a solvency story. It is a story about whether a business earning a third of its revenue as operating profit is at the start of a growth phase or the end of one.

Valuation

The gap between what this business earns and what it costs to run is the whole valuation question, so start there. In the fiscal year ended March 31, 2026 Doximity turned 644.9 million dollars of revenue into 214.9 million of operating income. Strip out the investment portfolio and the market is paying roughly 17 times that figure. Discounted at an 11.6% cost of capital, the price implies operating growth held at its self-funding ceiling for about six years.

Two of those inputs are worth separating. The rate is not the demanding part: the company's own recent record sits within the pace that calculation asks for. The duration is. Of comparable fast growers, only about 30% held that pace over a stretch that long, and the overall read rests on three of four available comparisons, leaning on the company's own history and that survival rate. That makes the conclusion weaker rather than gentler.

The methods used to triangulate the business split cleanly in two, and the split is informative. Peer-multiple approaches and the cash-flow approaches that credit forward growth both reach the price, and in fact land above it: capitalizing free cash flow of 326.5 million dollars and growing it lands well beyond where the shares trade, and applying the healthcare-software sector's earnings and sales multiples does the same. The static frames disagree. Asset-value approaches, which read book equity of about 4.77 dollars a share, and no-growth earnings-power approaches, which capitalize a five-year average operating profit with no expansion at all, both land under the price. That pattern describes a business the market is pricing for continued growth but not for a miracle. It is not the shape of a story stock.

The concrete requirement is unusually undemanding, which is the most surprising thing in the numbers. To support today's price the business needs to sustain operating margins near 10.8% on the kind of economics it has shown. It earned 33.3% in the fiscal year just closed. The margin has room to fall a long way before the arithmetic stops working, and that cushion is the real answer to the compression in the June quarter.

Cohort position supports the read rather than complicating it. VEEV earns a 28.8% operating margin on 3.32 billion dollars of revenue growing 16.2%. WAY earns 22.9% on 1.21 billion growing 19.2%. HNGE grows 51.3% and loses more than it earns. Doximity sits at the top of that group on margin and in the middle on growth, and it is the only one of the four carrying no funded debt.

Which is where the balance sheet closes the picture. Cash and marketable securities came to 748.6 million dollars at the March 2026 year end, against total liabilities of 172.9 million, of which the largest item is deferred revenue, money customers have already paid. There is nothing to refinance and no coverage ratio to worry about. The reason the multiple looks moderate is not that the market has mispriced a compounder; it is that the market has already marked down the growth rate, and the June quarter's 7% revenue increase is the number that will decide whether that markdown was enough.

Catalysts

The fiscal 2027 first-quarter results, released August 6, 2026, are the freshest read and the most complicated. Revenue of 156.6 million dollars grew 7% against the June 2025 quarter, the slowest growth the company has printed in some time, while net income fell to 24.3 million dollars from 53.3 million and operating cash flow fell 32% to 42.0 million. Chief Executive Jeff Tangney framed the quarter around the clinical AI product, saying the assistant "was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement".

Guidance is the part worth watching. For the fiscal year ending March 31, 2027 the company set revenue in a range of 671 to 681 million dollars, and for the September 2026 quarter a range of 170 to 171 million. Taken together those imply the growth rate improves through the year rather than staying at the June quarter's pace. That is the load-bearing assumption in the outlook, and the December and March quarters are when pharmaceutical marketing budgets are set and spent, so it will be tested twice before the year closes.

The cost side is the second thing to follow. Research and development, sales and marketing, and cost of revenue all grew faster than revenue in the June quarter, and stock compensation ran at 36.8 million dollars against 21.9 million a year earlier. Meanwhile the buyback continued at 91.6 million dollars in the quarter. Management is spending on the AI products and retiring shares at the same time, from a cash and securities balance that has been shrinking as it does so. Whether that combination is confidence or overreach is answered by whether the second-half revenue acceleration in the guidance actually arrives.

Peer Cohorts (Per Segment, With Filing Citations)

Cloud-based digital platform for medical professionals (single operating segment) (reported)

• VEEV (Veeva Systems Inc.)
• FY2025 10-K: …or as an integrated solution with multiple applications that enable customers to unify and manage important documents and related data in a single global system: • Veeva Clinical Platform advances clinical trial execution by providing a complete and connected technology ecosystem. Our clinical platform is designed to…
• FY2025 10-K: …data and data analytics providers. No single vendor offers products that compete with all of our Veeva Development Cloud or Quality Cloud applications, but IQVIA, Dassault Systèmes, OpenText Corporation, Oracle Corporation, Honeywell International Inc., and other smaller application providers offer applications that…
• HNGE (Hinge Health, Inc.)
• FY2025 10-K: …buy solution on the market. Our clients are primarily self-insured employers and include many of the nation's leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many public sector self-insured employers, such as state and local city governments and labor unions. In…
• FY2025 10-K: …and the easiest to buy solution on the market. Our clients are primarily self-insured employers and include many of the nation's leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many public sector self-insured employers, such as state and local city governments and…
• WAY (Waystar Holding Corp.)
• FY2025 10-K: $25 billion by 2030, driven by growth within healthcare payments (notably, in prior authorizations, patient payments, and revenue cycle management analytics), increased outsourcing in revenue cycle management, as well as secular technology tailwinds such as greater utilization of AI. We expect to expand our TAM…
• FY2025 10-K: …root cause analysis to help providers reduce the chance of denials in future claims. • Clinical integrity and revenue capture. Our platform integrates AI-powerd automation with clinical insight to transform mid-cycle performance, enabling providers to capture revenue accurately and prevent losses early. By unifying…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.